150 related articles for article (PubMed ID: 9156034)
1. Elevation of circulating proadrenomedullin-N terminal 20-peptide in thyrotoxicosis.
Taniyama M; Kitamura K; Ban Y; Sugita E; Ito K; Katagiri T
Clin Endocrinol (Oxf); 1997 Mar; 46(3):271-4. PubMed ID: 9156034
[TBL] [Abstract][Full Text] [Related]
2. Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels.
Etoh T; Kato J; Takenaga M; Imamura T; Kitamura K; Koiwaya Y; Eto T
Clin Cardiol; 1999 Feb; 22(2):113-7. PubMed ID: 10068849
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma adrenomedullin level in hyperthyroidism.
Taniyama M; Kitamura K; Ban Y; Eto T; Katagiri T
Eur J Clin Invest; 1996 Jun; 26(6):454-6. PubMed ID: 8817157
[TBL] [Abstract][Full Text] [Related]
4. Decrease of TSH levels and epithelium/colloid ratio in rat thyroid glands following administration of proadrenomedullin N-terminal peptide (12-20).
Ginda WJ; Nowak KW; Malendowicz LK
Horm Metab Res; 2000 Jan; 32(1):10-4. PubMed ID: 10727007
[TBL] [Abstract][Full Text] [Related]
5. Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans.
Kita T; Kitamura K; Kuwasako K; Kawamoto M; Eto T
J Hypertens; 1998 Dec; 16(12 Pt 2):2057-62. PubMed ID: 9886897
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of proadrenomedullin N-terminal 20 peptide and adrenomedullin in patients undergoing hemodialysis.
Tokura T; Kinoshita H; Fujimoto S; Kitamura K; Eto T
Nephron Clin Pract; 2003; 95(2):c67-72. PubMed ID: 14610332
[TBL] [Abstract][Full Text] [Related]
7. Plasma and urine levels of adrenomedullin and proadrenomedullin N-terminal 20 peptide in chronic glomerulonephritis.
Kinoshita H; Fujimoto S; Kitamura K; Yokota N; Kawamoto M; Tokura T; Hisanaga S; Eto T
Am J Kidney Dis; 1999 Jul; 34(1):114-9. PubMed ID: 10401024
[TBL] [Abstract][Full Text] [Related]
8. Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat model of endotoxin shock.
Matsui E; Kitamura K; Yoshida M; Kato J; Asada Y; Sumiyoshi A; Eto T
Hypertens Res; 2001 Sep; 24(5):543-9. PubMed ID: 11675949
[TBL] [Abstract][Full Text] [Related]
9. Expression of proadrenomedullin derived peptides in the mammalian pituitary: co-localization of follicle stimulating hormone and proadrenomedullin N-20 terminal peptide-like peptide in the same secretory granules of the gonadotropes.
Montuenga LM; Burrell MA; Garayoa M; Llopiz D; Vos M; Moody T; García-Ros D; Martínez A; Villaro AC; Elsasser T; Cuttitta F
J Neuroendocrinol; 2000 Jul; 12(7):607-17. PubMed ID: 10849205
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) in adrenal chromaffin cells.
Kobayashi H; Yanagita T; Yokoo H; Wada A
Peptides; 2001 Nov; 22(11):1895-901. PubMed ID: 11754978
[TBL] [Abstract][Full Text] [Related]
11. Secretion of proadrenomedullin N-terminal 20 peptide from cultured neonatal rat cardiac cells.
Tsuruda T; Kato J; Kitamura K; Kuwasako K; Imamura T; Koiwaya Y; Kangawa K; Eto T
Life Sci; 2001 Jun; 69(2):239-45. PubMed ID: 11441914
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone augments adrenomedullin production without stimulating pro-adrenomedullin N-terminal 20 peptide secretion in vascular smooth muscle cells.
Uemura T; Kato J; Kuwasako K; Kitamura K; Kangawa K; Eto T
J Hypertens; 2002 Jun; 20(6):1209-14. PubMed ID: 12023693
[TBL] [Abstract][Full Text] [Related]
13. Distribution and molecular forms of adrenomedullin and proadrenomedullin N-terminal 20 peptide in the porcine gastrointestinal tract.
Kiyomizu A; Kitamura K; Kawamoto M; Eto T
J Gastroenterol; 2001 Jan; 36(1):18-23. PubMed ID: 11211206
[TBL] [Abstract][Full Text] [Related]
14. Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension.
Kuwasako K; Kitamura K; Kangawa K; Ishiyama Y; Kato J; Eto T
Ann Clin Biochem; 1999 Sep; 36 ( Pt 5)():622-8. PubMed ID: 10505213
[TBL] [Abstract][Full Text] [Related]
15. Hypotensive effect of a newly identified peptide, proadrenomedullin N-terminal 20 peptide.
Shimosawa T; Fujita T
Hypertension; 1996 Sep; 28(3):325-9. PubMed ID: 8794811
[TBL] [Abstract][Full Text] [Related]
16. [Adrenomedullin and PAMP].
Kitamura K; Eto T
Nihon Rinsho; 1997 Aug; 55(8):1963-70. PubMed ID: 9284408
[TBL] [Abstract][Full Text] [Related]
17. A newly identified peptide, proadrenomedullin N-terminal 20 peptide, induces hypotensive action via pertussis toxin-sensitive mechanisms.
Shimosawa T; Ando K; Fujita T
Hypertension; 1997 Nov; 30(5):1009-14. PubMed ID: 9369247
[TBL] [Abstract][Full Text] [Related]
18. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions.
Kitamura K; Kangawa K; Eto T
Microsc Res Tech; 2002 Apr; 57(1):3-13. PubMed ID: 11921351
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive proadrenomedullin N-terminal 20 peptide in human tissue, plasma and urine.
Washimine H; Kitamura K; Ichiki Y; Yamamoto Y; Kangawa K; Matsuo H; Eto T
Biochem Biophys Res Commun; 1994 Jul; 202(2):1081-7. PubMed ID: 8048921
[TBL] [Abstract][Full Text] [Related]
20. Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate and in prostate carcinoma.
Calvo A; Abasolo I; Jiménez N; Wang Z; Montuenga L
Microsc Res Tech; 2002 Apr; 57(2):98-104. PubMed ID: 11921360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
